A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

657

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG: Abatacept
DRUG: Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)
DRUG: Upadacitinib
DRUG: Placebo for upadacitinib

Sponsor

AbbVie